摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-苯基呋喃并[2,3-D]嘧啶-4-胺 | 18031-97-5

中文名称
6-苯基呋喃并[2,3-D]嘧啶-4-胺
中文别名
(6-苯基呋喃[3,2-E]嘧啶-4-基)胺;6-苯基呋喃[3,2-E]嘧啶-4-胺;6-苯基-4-呋喃[3,2-E]嘧啶胺;6-苯基呋喃[2,3-D]嘧啶-4-胺
英文名称
4-amino-6-phenylfuro[2,3-d]pyrimidine
英文别名
6-phenyl-furo[2,3-d]pyrimidin-2-ylamine;4-amino-6-phenylfuro-[2,3-d]pyrimidine;6-phenylfuro[2,3-d]pyrimidine-4-amine;6-Phenylfuro[2,3-d]pyrimidin-4-amine
6-苯基呋喃并[2,3-D]嘧啶-4-胺化学式
CAS
18031-97-5
化学式
C12H9N3O
mdl
MFCD01096907
分子量
211.223
InChiKey
KLUPXPVKDBPOMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    296-298 °C
  • 沸点:
    420.2±40.0 °C(Predicted)
  • 密度:
    1.317±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    64.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090

SDS

SDS:c86cbdb74d80ab18f6ccb7e76ad22094
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF
    申请人:Lampe Thomas
    公开号:US20110166163A1
    公开(公告)日:2011-07-07
    The present application relates to novel substituted furopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.
    本申请涉及新型的取代呋喃嘧啶生物,及其制备过程,用于治疗和/或预防疾病,以及用于制备用于治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。
  • Nitrogen-containing aromatic derivatives
    申请人:——
    公开号:US20040053908A1
    公开(公告)日:2004-03-18
    Compounds represented by the following general formula: 1 [wherein A g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X g is —O—, —S—, etc.; Y g is an optionally substituted C 6 - 14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T g1 is a group represented by the following general formula: 2 (wherein E g is a single bond or —N(R g2 )—, R g1 and R g2 each independently represent a hydrogen atom, an optionally substituted C 1-6 alkyl group, etc. and Z g represents a C 1-8 alkyl group, a C 3-8 alicyclic hydrocarbon group, a C 6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.
    由以下一般式表示的化合物: 1 [其中 A g 是可选择地取代的5-至14-成员杂环基团,等等;X g 是—O—,—S—,等等;Y g 是可选择地取代的C 6 - 14 芳基团,可选择地取代的5-至14-成员杂环基团,等等;以及 T g1 是由以下一般式表示的基团: 2 [其中 E g 是单键或—N(R g2 )—,R g1 和R g2 各自独立地表示氢原子,可选择地取代的C 1-6 烷基基团,等等,Z g 表示C 1-8 烷基基团,C 3-8 脂环烃基团,C 6-14 芳基团,等等], 其盐或上述化合物的合物。
  • Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof
    申请人:Lampe Thomas
    公开号:US20090318475A1
    公开(公告)日:2009-12-24
    The present application relates to novel, acyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.
    本申请涉及新颖的、非环式取代的呋噻嘧啶生物,其生产方法,它们用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物制剂,特别是用于治疗和/或预防心血管疾病。
  • TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF
    申请人:Lampe Thomas
    公开号:US20100267749A1
    公开(公告)日:2010-10-21
    The invention relates to the novel 4,5,6-trisubstituted furo[2,3-d]pyrimidine derivatives of formula (I), to methods for their production, their use in the treatment and/or prophylaxis of diseases and their use in the production of drugs for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.
    该发明涉及公式(I)的新颖的4,5,6-三取代噻吩[2,3-d]嘧啶生物,以及它们的生产方法,它们在治疗和/或预防疾病中的用途,以及它们在生产用于治疗和/或预防疾病的药物中的用途,特别是用于治疗和/或预防心血管疾病。
  • 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors
    作者:Yutaka Maeda、Masato Nakano、Hideyuki Sato、Yasushi Miyazaki、Stephanie L Schweiker、Jeffery L Smith、Anne T Truesdale
    DOI:10.1016/j.bmcl.2004.05.064
    日期:2004.8
    Modeling studies of a furo[2,3-d]pyrimidine GSK-3 hit compound 1 superimposed onto the X-ray crystal structure of a legacy pyrazolo[3,4-c]pyridazine GSK-3 inhibitor 2 led to the identification of 4-acylamino-6-arylfuro[2,3-d]pyrimidine template 3. Synthesis of analogues based on template 3 has resulted in a number of potent and selective GSK-3beta inhibitors. The most potent and selective compound
    呋喃[2,3-d]嘧啶GSK-3命中化合物1叠加在传统吡唑并[3,4-c]哒嗪GSK-3抑制剂2的X射线晶体结构上的模型研究导致鉴定出4 -酰基基-6-芳基呋喃[2,3-d]嘧啶模板3。基于模板3的类似物的合成产生了许多有效的和选择性的GSK-3beta抑制剂。最有效和选择性最大的化合物是间吡啶类似物24。
查看更多

同类化合物

呋喃并[2,3-d]嘧啶-4(1H)-酮 呋喃并[2,3-d]嘧啶-2(3H)-酮 呋喃并[2,3-d]嘧啶 6-苯基呋喃并[2,3-D]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4(3H)-酮 6-(4-甲氧基苯基)呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲氧基苯基)-5-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲基苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(4-氯苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(3-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 5-甲基呋喃并[2,3-d]嘧啶-4-胺 5-溴呋喃并[2,3-D]嘧啶-4-胺 5-氯甲基呋喃并[2,3-d]嘧啶-2,4-二胺 5,6-二甲基呋喃[2,3-d]嘧啶-4-胺 4-氯呋喃[2,3-D]嘧啶 4-氯-6-甲基-呋喃并[2,3-d]嘧啶 4-氨基呋喃并[2,3-D]嘧啶 4,6-二甲基呋喃并[2,3-d]嘧啶 4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 3-(2-脱氧-beta-D-赤式-呋喃戊糖基)-6-甲基呋喃并[2,3-d]嘧啶-2(3H)-酮 2-甲基硫代呋喃并[2,3-d]嘧啶-6-甲醇 2,4-二氯呋喃并[2,3-d]嘧啶 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 2-Methyl-4-diacetylamino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[1-methyl-6-(5-nitro-furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-propan-1-ol 1-Methyl-4-(1-methyl-2-methoxy-ethyl-amino)-6-(5-nitro-2-furyl)-1H-pyrazolo<3.4-d>pyrimidin 2-Ethyl-4-amino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[3’,5’-di-O-(tert-butyldimethylsilyl)-2’-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2,6-dimethyl-3H-furo[2,3-d]pyrimidine-4-thione 4-hydrazino-6-methyl-2-phenyl-furo[2,3-d]pyrimidine 3-[3'-O-(tert-butyldimethylsilyl)-2'-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 4-Ethylamino-6-methylfuro<4,5-b>pyrimidin 6-[Diethoxy(oxido)phosphaniumyl]furo[2,3-d]pyrimidine t counted 4-methoxy-2,6-dimethyl-furo[2,3-d]pyrimidine 3-(2-deoxy-β-D-erythro-pentofuranosyl)-6-ethynyl-furo[2,3-d]pyrimidin-2(3H)-one ethyl (4-oxo-5-phenyl-3,4-dihydrofuro[2,3-d]pyrimidin-2-yl)acetate 2,2'-[3-methyl-6-(5-nitro-furan-2-yl)-isoxazolo[5,4-d]pyrimidin-4-ylazanediyl]-bis-ethanol 5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-acetyl-6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine 5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine furan-2-carboxylic acid N'-{2-amino-7-[2-(t-butyldimethylsilanyloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-hydrazide 2-(5-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethanol 5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine tert-butyl 3-<6'-(benzyloxy)-2',4'-dimethylfuro<2,3-b>-pyrid-5'-yl>-3-hydroxybutanoate 6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine-5-carboxaldehyde